Glucose Variability Pilot Study for the Abbott Sensor Based Glucose Monitoring System-Professional
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02336945|
Recruitment Status : Completed
First Posted : January 13, 2015
Last Update Posted : January 24, 2017
- Study Details
- Tabular View
- No Results Posted
- How to Read a Study Record
|Condition or disease||Intervention/treatment|
|Type 2 Diabetes Mellitus||Device: Abbott Sensor Based Glucose Monitoring System-Professional|
Subjects will wear two Sensors, one applied to the back of each upper arm, for a period of 14 days. Subjects will wear the Sensor while going about their normal daily activities during the home use period. Subjects will not be able to see any glucose data. The devices will be removed at the completion of the final study visit.
Data obtained from the Reader and reports generated by the system will not be used by the subject or the research team members to determine treatment. Subjects must adhere to their diabetes clinical management plan established prior to the study.
No additional medical care will be provided to study subjects following study completion other than care related to the follow up and treatment of adverse events.
|Study Type :||Observational|
|Actual Enrollment :||146 participants|
|Official Title:||Glucose Variability Pilot Study for the Abbott Sensor Based Glucose Monitoring System-Professional|
|Study Start Date :||January 2015|
|Actual Primary Completion Date :||July 2015|
|Actual Study Completion Date :||July 2015|
Type 2 diabetes
Subjects with type 2 diabetes who meet one of the therapy conditions
Device: Abbott Sensor Based Glucose Monitoring System-Professional
Subjects will wear 2 glucose sensors while going about daily activities and adhering to establish diabetes treatment plan. This is not a treatment study.
Other Name: FreeStyle Libre Pro
- Glucose variability as measured by AGP Interquartile Range, (IQR) obtained via System-Pro Sensor. [ Time Frame: 2 weeks ]
- Assessment of ambulatory glucose profiles (AGPs) generated by the Software [ Time Frame: 2 weeks ]
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||18 Years and older (Adult, Older Adult)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||No|
|Sampling Method:||Non-Probability Sample|
- Subject must be at least 18 years of age.
- Subject must have diagnosis of type 2 diabetes prior to enrollment.
- Subject must have been on current treatment regimen for at least 6 months prior to enrollment and must remain on therapy regimen for the duration of the study (subjects diagnosed within last 6 months must be on no medication both prior to and throughout the study to enroll).
HbA1c greater than or equal to 6.0% or less than or equal to 12.0% as demonstrated by lab HbA1c result obtained within the last 6 months.
- Subjects with HbA1c <7.5% will be excluded from the study if the subject's intended therapy group for enrollment requires an HbA1c ≥7.5%.
- For therapy groups enrolling 12 subjects with HbA1c of <7.5% and 12 subjects with HbA1c of ≥7.5%, subjects with an HbA1c level within each respective range will be excluded from the study once the enrollment goal of that HbA1c range has been met.
- If no HbA1c taken within the last six months is available, a new laboratory HbA1c value must be obtained prior to Sensor application.
- Subject must be able to read and understand English.
- In the investigator's opinion, the subject must be able to follow the instructions provided to him/her by the study site and perform all study tasks as specified by the protocol
- In the investigators opinion, the subject must be compliant with their diabetes management plan and must be able to adhere to medication regimen throughout study.
- Subject must be available to participate in all study visits.
- Subject must be willing and able to provide written signed and dated informed consent.
- Subject has known allergy to medical grade adhesive or isopropyl alcohol used to disinfect skin.
- Subject is pregnant, is attempting to conceive or is not willing and able to practice birth control during the study duration (applicable to female subjects only).
- Subject has skin lesions, scarring, redness, infection or edema at the application sites that could interfere with device placement or the accuracy of interstitial glucose measurements.
- Subject currently is participating in another clinical trial.
- Subject has X-ray, MRI or CT appointment scheduled during the period of study participation, and the appointment cannot be rescheduled for a time before study participation starts or after study participation ends.
- HbA1c of less than 6.0% or greater than 12.0% as demonstrated by lab HbA1c result obtained within the last 6 months.
- Enrollment goal of Subject's intended therapy group has been met.
- Subject is unsuitable for participation due to any other cause as determined by the Investigator.
Subject is currently on one of the following treatments or treatment combinations:
- Metformin + Sulfonylurea + DPP-4 Inhibitor
- Sulfonylurea + DPP-4 Inhibitor
- Metformin + Sulfonylurea + GLP-1 Receptor Agonist
- Sulfonylurea + GLP-1 Receptor Agonist
- Metformin + Sulfonylurea + SGLT-2
- Sulfonylurea + SGLT-2
- Metformin + SGLT-2 + Insulin
- SGLT-2 + Insulin
- NPH Insulin (with exception of NPH insulin present in premix formulations)
- Rapid acting insulin (with exception of rapid acting insulin present in premix formulations)
- Four (4) or more diabetes therapies
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02336945
|United States, California|
|Unger Primary Care Medical Center & Catalina Research Institute|
|Chino, California, United States, 91710|
|Dr. Deanna Cheung|
|Long Beach, California, United States, 90807|
|University of California San Diego Veterns Affairs Medical Center|
|San Diego, California, United States, 92161|
|United States, Michigan|
|Henry Ford Medical Center|
|Detroit, Michigan, United States, 48202|
|United States, Missouri|
|St. Luke's Endocrinology and Diabetes|
|Kansas City, Missouri, United States, 64111|
|United States, North Carolina|
|Duke Southern Regional AHEC|
|Fayetteville, North Carolina, United States, 28304|
|United States, Texas|
|Diabetes America- Pearland|
|Pearland, Texas, United States, 77584|
|Responsible Party:||Abbott Diabetes Care|
|Other Study ID Numbers:||
|First Posted:||January 13, 2015 Key Record Dates|
|Last Update Posted:||January 24, 2017|
|Last Verified:||August 2015|
Diabetes Mellitus, Type 2
Glucose Metabolism Disorders
Endocrine System Diseases